Erol C. Vatansever

MedicineComputer ScienceChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**”.

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

ChemMedChem(2020)10.1002/cmdc.202000924

N/A

0.736DataRank · unranked

134 citations

R. Xinyu, Yuying Ma, Yugendar R. Alugubelli, Danielle A. Scott, Erol C. Vatansever +17 more

An optimal “Click” formulation strategy for antibody-drug conjugate synthesis

Bioorganic & Medicinal Chemistry(2020)10.1016/j.bmc.2020.115808

N/A

0DataRank · unranked

13 citations

Jeffrey Kang, Alfred Tuley, E. Sally Ward, Wenshe Ray Liu, Erol C. Vatansever

Bepridil is potent against SARS-CoV-2 In Vitro

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.23.112235

N/A

0DataRank · unranked

30 citations

Kai S. Yang, Kaci C. Kratch, Aleksandra Drelich, Chia-Chuan Cho, Drake M. Mellott +4 more

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.07.28.223784

N/A

0DataRank · unranked

10 citations

R. Xinyu, Yuying Ma, Yugendar R. Alugubelli, Danielle A. Scott, Erol C. Vatansever +17 more

The P3 O - Tert -Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.12.18.473326

N/A

0DataRank · unranked

3 citations

Kai S. Yang, Zhi Geng, Yugendar R. Alugubelli, Namir Shaabani, Erol C. Vatansever +12 more

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals

European Journal of Medicinal Chemistry(2022)10.1016/j.ejmech.2022.114596

N/A

0DataRank · unranked

55 citations

Zhi Geng, Kai S. Yang, Namir Shaabani, Kaustav Khatua, R. Xinyu +13 more

A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals

European Journal of Medicinal Chemistry(2022)10.1016/j.ejmech.2022.114570

N/A

0DataRank · unranked

43 citations

Kai S. Yang, Zhi Geng, Yugendar R. Alugubelli, Namir Shaabani, Erol C. Vatansever +13 more

A Designed, Highly Efficient Pyrrolysyl-tRNA Synthetase Mutant Binds o-Chlorophenylalanine Using Two Halogen Bonds

Journal of Molecular Biology(2022)10.1016/j.jmb.2022.167534

N/A

0DataRank · unranked

15 citations

Kai S. Yang, Zhi Geng, Yuchen Qiao, Pingwei Li, Shiqing Xu +2 more

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

Journal of Medicinal Chemistry(2023)10.1021/acs.jmedchem.3c00221

N/A

0DataRank · unranked

25 citations

Sandeep Atla, Namir Shaabani, Veerabhadra R. Vulupala, Kai S. Yang, Yugendar R. Alugubelli +13 more

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.17.524469

N/A

0DataRank · unranked

4 citations

Sandeep Atla, Namir Shaabani, Veerabhadra R. Vulupala, Kai S. Yang, Yugendar R. Alugubelli +13 more

An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.11.536467

N/A

0DataRank · unranked

3 citations

Yugendar R. Alugubelli, Kai S. Yang, Veerabhadra R. Vulupala, Lauren R. Blankenship, Demonta Coleman +14 more

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

Antiviral Research(2024)10.1016/j.antiviral.2024.105874

N/A

0DataRank · unranked

11 citations

Yugendar R. Alugubelli, Kai S. Yang, Veerabhadra R. Vulupala, Lauren R. Blankenship, Demonta Coleman +15 more